DNLI
DNLI
US24823R1059
Denali Therapeutics Inc.
Loading chart...

Valuation & History

Quarterly trend of key valuation metrics

Metric
Current (TTM) TTM Baseline
Q2 '26 30.06.2026
Q1 '26 31.03.2026
Q4 '25 31.12.2025
Market & Enterprise Value
Market Cap
3.11B EUR
4.11B EUR
3.05B EUR
2.58B EUR
Enterprise Value
2.31B EUR
3.94B EUR
2.69B EUR
2.41B EUR
Valuation Multiples
Trailing P/E
--
--
--
--
Forward P/E
-8.04x
--
--
--
Price to Sales
862.66x
1,140.1x
--
--
Price to Book
3.72x
4.92x
3.29x
2.54x
EV/Revenue
641.39x
1,093.12x
--
--
EV/EBITDA
-4.39x
--
--
--
Price to FCF (P/FCF)
--
--
--
--
EV/FCF
--
--
--
--
FCF Yield
-8.64%
-11.35%
-13.76%
-11.07%
ende